10x Genomics, Inc. (TXG): what the price assumes

In the published model solve dated 2026-Q2, anchored at $47.48, 10x Genomics, Inc. (TXG) is priced for today's economics sustained for ~20.0 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-11.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/TXG

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.

Solve inputs: computed at a 15% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~3.2 years.

Reconcile: at the x-ray's 9.3% required return this reads ~6.8 years; the models below use their own rates.

How unusual the bet is: elevated

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.1%); the inversion above states its own rate.

Per-Model Detail (n=4)

Solvency

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Operating profit is negative or near zero and there is no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so interest coverage cannot be computed honestly.

Bullet Takeaways

• 10x Genomics sells single-cell and spatial-biology instruments plus the consumables that run on them, a razor-and-blade model for academic and biopharma labs, but its core is shrinking: the 10-K discloses single-cell solutions revenue fell from $407.5 million in 2024 to $385.9 million in 2025 (accession 0001628280-26-007822).
• The dominant risk is customer funding, which the company cannot control: the filing notes that in March 2025 the NIH terminated approximately 700 research grants totaling more than $2.4 billion, and that funding disruptions have caused customers to reduce, delay, or cancel purchases (same accession).
• Watch the second-half 2026 launch of the new Atera spatial platform and the maintained full-year revenue guidance of $600 to $625 million, which implies roughly 0% to 4% growth once the 2025 one-time litigation revenue is stripped out.

Bull Case

The market is paying a premium multiple for a company whose reported numbers look stalled, and the bull case is that the reported numbers understate what is actually happening. First-quarter 2026 revenue of $150.8 million was down 3% year over year, but that comparison carries a $16.8 million one-time license and royalty item in the 2025 base; strip it out and revenue grew 9%. Underneath, consumables revenue rose 13% and gross margin improved to 70%, the signal that matters most for a razor-and-blade instruments company: the installed base is running more experiments even while new instrument sales are soft. The 10-K frames the strategy plainly, that lowering prices "can expand usage" and that "increased adoption and volume growth will drive higher overall sales of our instruments and consumables over" time (accession 0001628280-26-007822). Recurring consumables, not one-time instrument placements, are where the durable economics live.

The platform is the moat. 10x's tools let researchers "interrogate biological systems at previously inaccessible resolution and scale" and have enabled discoveries across "oncology, immunology and neuroscience" (same accession), the kind of embedded position in academic and biopharma workflows that is hard to displace once protocols and published papers are built around it. The next leg is Atera, a whole-transcriptome spatial platform launched in 2026 with shipments expected in the second half, and early-access data from research institutes showing high-resolution tumor-microenvironment mapping. A genuinely new measurement capability can pull a fresh instrument-and-consumables cycle behind it.

The balance sheet buys time for the cycle to turn. 10x holds net cash with a current ratio of 5.9, book value of $6.35 per share, and it generated positive free cash flow in all four of the last four quarters, unusual for a company still posting operating losses. The years of patent litigation that clouded the story have largely resolved in the company's favor, including a May 2025 settlement and license agreements with Bruker "resolving all outstanding litigation and other proceedings" (accession 0001628280-26-007822) and a 2026 settlement with Curio. The bull case is a category-defining tools franchise with improving consumables demand and a new platform, trading through a temporary academic-funding air pocket the market is extrapolating too far.

Bear Case

The capital-allocation and revenue-quality picture deserves the first look, because it flatters the recent past. A meaningful slice of 2025 revenue and reported gains came not from selling more instruments but from settling patent fights: the 10-K describes a Vizgen settlement gain determined "by applying a royalty rate to Vizgen's historical revenues" and the Bruker settlement and license agreements (accession 0001628280-26-007822). Litigation proceeds are real cash, but they are non-recurring, and 2026 guidance of $600 to $625 million implies roughly 0% to 4% growth once that 2025 windfall is removed. Management has spent years and considerable legal cost defending an IP estate, and while that protects the franchise, it also means a portion of recent results reflects the courtroom rather than the market. Book value is $6.35 per share against a $42.62 stock, so almost none of the price is anchored to net worth.

The demand side is genuinely deteriorating in the core, and the company says so. Single-cell solutions revenue fell from $407.5 million in 2024 to $385.9 million in 2025 (same accession), and the customer base sits squarely on top of the one funding source now under pressure: the filing notes the NIH terminated roughly 700 grants worth more than $2.4 billion in March 2025 and warns that funding disruptions cause customers to "reduce, delay or cancel purchases of our products" (accession 0001628280-26-007822). Management has repeatedly described a challenging capital-equipment environment constraining instrument sales. Academic and government research budgets are the demand engine, and that engine is being throttled by policy the company cannot influence.

The valuation leaves no room for any of it. At about 8 times revenue with the business losing money at the operating line (about minus 6% margin), the price assumes 10x eventually earns a roughly 28% operating margin and grows near its self-funding ceiling for about 18 years; historically only about 14% of comparable fast-growers sustained such a pace even ten years. Not one valuation family reaches the price, the asset-value lens reads it at about 7 times, earnings power at 5.5 times, and even the peer-multiple lens at over 3 times what it supports, so the market is paying a bet beyond what any standard frame justifies. A company with flat-to-declining core revenue, a funding-constrained customer base, and no current operating profit is priced as a durable high-margin compounder. The bear case is that the premium was built during a litigation-boosted, pre-funding-shock window that has now closed.

Valuation

Because 10x is not earning an operating profit, the price is set against sales, and at $42.62 (July 11, 2026) the stock trades near 8 times revenue. That multiple only resolves if the business eventually reaches roughly a 28% operating margin, held as an input to the inversion, while growing near its self-funding ceiling for about 18 years. It earns about minus 6% at the operating line today. The framework labels the priced-in assumption elevated, and the base rate is thin: only about 14% of comparable fast-growers sustained that growth pace even ten years. One measurement note keeps the arithmetic clean, the inversion works from a normalized operating income near $173 million while the trailing EDGAR figure is about minus $39 million, so the two are different bases, not one number.

The method families are unanimous in the direction that matters: none reaches the price. The asset-value lens lands at about 7 times below it, earnings power at 5.5 times, and the peer-multiple lens at over 3 times, with the distress-related projection methods skipped entirely because sustained losses make them unreliable. That unanimity is the signal, the spread is not a debate about how expensive the stock is but agreement that the price sits above every standard frame, and the gap is the premium the market pays for the platform and the Atera optionality. The filing-sourced facts under that premium cut both ways: consumables are the durable economics 10x is trying to grow, and the same filing concedes single-cell revenue fell to $385.9 million in 2025 from $407.5 million in 2024 (accession 0001628280-26-007822), so the core the multiple rests on is currently shrinking, not compounding.

Solvency is not the concern; the balance sheet is net cash with a 5.9 current ratio, so there is no financial pressure on the path to the priced-in outcome, and the company generated positive free cash flow in each of the last four quarters. The concern is that the premium underwrites a turnaround, not just growth: the price needs a loss-making business to become a high-margin one and to grow for the better part of two decades, at a moment when its academic-and-government customer base is funding-constrained and its largest product line is contracting. What the buyer at $42.62 owns is the Atera launch and the eventual recovery of research spending; every valuation lens that credits only today's economics prices the stock between roughly $6 and $14, and the distance from there to the current price is the size of the bet.

Catalysts

The May 7 first-quarter report set the tone for the year. Revenue of $150.8 million was down 3% year over year, but excluding $16.8 million of one-time 2025 license and royalty revenue it rose 9%, gross margin improved to 70%, and consumables revenue grew 13%. Management maintained full-year 2026 revenue guidance of $600 to $625 million, which represents roughly 0% to 4% growth once the non-recurring 2025 settlement revenue is excluded, and repeatedly flagged a challenging capital-equipment environment weighing on instrument sales.

The forward catalysts are one product and one policy variable. Atera, the new whole-transcriptome spatial platform, is expected to begin shipping in the second half of 2026, with early-access data from research institutes showing high-resolution tumor-microenvironment mapping; a successful ramp would test whether a new capability can restart the instrument cycle. The larger swing factor is research funding: the company's recovery is closely tied to the flow of NIH and academic budgets, a point analysts have made explicitly, and the 10-K quantifies the shock with the March 2025 termination of about 700 grants worth over $2.4 billion (accession 0001628280-26-007822). The patent-litigation overhang, by contrast, has mostly lifted, with the Bruker settlement in 2025 and a Curio settlement in 2026 removing distractions and legal cost. The next quarterly print and the Atera shipment timeline are the near-term checkpoints on whether the consumables strength can offset a funding-constrained instrument market.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• ILMN (Illumina, Inc.)
• FY2025 10-K: …decreased primarily due to higher costs related to tariffs and a $23 million intangible asset impairment, partially offset by lower strategic partnership revenue, that is lower margin, and a more favorable product mix towards consumables. Consolidated gross margin was 66.1% in 2025 compared to 65.4% in 2024, and the…
• FY2025 10-K: …among sequencing and non-sequencing products that are designed to address the same use case or answer the same biological question. Some of our competitors have, or will have, substantially greater financial, technical, research, artificial intelligence capabilities, and other resources than we do, along with larger,…
• BIO (Bio-Rad Laboratories, Inc.)
• FY2025 10-K: …We believe this direct commercial model enables effective portfolio coverage, deeper customer engagement, and the development of long-term customer relationships. We also use a range of sales and marketing intermediaries ("SMIs") in our international markets. The types of SMIs we utilize are distributors, agents,…
• FY2025 10-K: …producers and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are primarily sold to hospital…
• BRKR (BRUKER CORPORATION)
• FY2025 10-K: …will depend on our ability to develop proprietary products that reach our target markets in a timely manner and are technologically superior to and/or less expensive, or more cost effective, than products marketed by our competitors. Current competitors or other companies may possess or develop technologies and…
• FY2025 10-K: …resources to internal and collaborative research and development projects. This level of investment in research and development has historically exceeded the industry average and reflects our commitment to scientific research and technological advancement to provide innovative products and solutions to our customers…
• RVTY (REVVITY, INC)
• FY2025 10-K: …segment revenue was driven by our Software business. Our consolidated gross margin decreased 104 basis points in fiscal year 2025, as compared to fiscal year 2024, primarily due to increased tariffs, unfavorable changes in foreign exchange rates, and product mix shift, partially offset by the completion of product…
• FY2025 10-K: …the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The CODM of the Company is the Chief Executive Officer ("CEO"). The CEO evaluates the performance of its operating segments based on revenue and operating income as adjusted for…
• A (AGILENT TECHNOLOGIES, INC.)
• FY2025 10-K: …and polyfluoroalkyl substances ("PFAS") into the environmental market. 50 Table of Contents Looking Forward. While the recent tariff changes adversely impacted our costs of revenue for the second half of fiscal year 2025, we expect to substantially mitigate the impact during our fiscal year 2026. Therefore, we remain…
• FY2025 10-K: …expenses attributed to business exit activities, lower variable pay and lower salary expense related to workforce reduction activities partially offset by higher infrastructure costs. Operating margin was relatively flat in 2025 when compared to 2024. Operating margin was flat due to lower salary expense related to…
• WAT (Waters Corporation)
• FY2025 10-K: …strategies of the Company's customers, which in turn could adversely impact the Company's results of operations or financial condition. The Company typically experiences seasonality in its orders that is reflected as an increase in sales in its fourth quarter as a result of purchasing habits for capital goods by…
• FY2025 10-K: …in particular, the portion related to the Company's HPLC, UPLC, LC-MS, light scattering, thermal analysis, rheometry and calorimetry product lines, is highly competitive. The Company encounters significant competition from several international instrument suppliers and other companies in both domestic and foreign…
• MTD (Mettler-Toledo International Inc.)
• FY2025 10-K: …and Analysis of Financial Condition and Results of Operations under "Results of Operations by Reportable Segment" for detailed results by segment and geographic region. We manufacture a wide variety of precision instruments and provide value-added services to our customers. Our principal products and services are…
• FY2025 10-K: …and it may be difficult for us to preserve operating margins, gain market share, and maintain a technological advantage. Our markets are highly competitive. Many are fragmented both geographically and by application, particularly the industrial and food retailing markets. As a result, we have numerous regional or…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.